CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Vitrolife is a global company contributing products within the IVF (in vitro fertilisation) field. Founded in 1994, Vitrolife was one of the first companies providing IVF laboratories with high quality ready-to-use culture media. Today its portfolio holds products all the way from oocyte retrieval to transfer of the embryo. The company collaborates with several researchers within the field of ART, both universities and clinics. Vitrolife has approximately 370 employees and its headquarters are located in Sweden with additional locations and production facilities in more than ten countries worldwide. The company has sales in more than 110 countries. The Vitrolife share is listed on the NASDAQ Stockholm, Nordic Mid Cap. To learn the latest Vitrolife (VITR) share price, follow Capital.com.
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.